A Study on the Clinical Course and Antimicrobial Susceptibility of <i>Mycoplasma pneumoniae </i>in a Community Hospital

DOI Web Site Web Site 14 References
  • SAKAI Takahiro
    Department of Respiratory Medicine, Kurashiki Central Hospital Department of Respiratory Medicin, Fukui prefectural Hospital
  • ISHIDA Tadasi
    Department of Respiratory Medicine, Kurashiki Central Hospital
  • ARITA Machiko
    Department of Respiratory Medicine, Kurashiki Central Hospital
  • TACHIBANA Hiromasa
    Department of Respiratory Medicine, Kurashiki Central Hospital
  • YOSHIOKA Hiroshige
    Department of Respiratory Medicine, Kurashiki Central Hospital
  • NOYAMA Maki
    Department of Respiratory Medicine, Kurashiki Central Hospital
  • TOKIOKA Fumiaki
    Department of Respiratory Medicine, Kurashiki Central Hospital
  • ITO Akihiro
    Department of Respiratory Medicine, Kurashiki Central Hospital
  • FURUTA Kenjiro
    Department of Respiratory Medicine, Kurashiki Central Hospital
  • NISHIYAMA Akihiro
    Department of Respiratory Medicine, Kurashiki Central Hospital
  • HASHIMOTO Toru
    Department of Clinical Laboratory, Kurashiki central Hospital
  • FUJII Hiroyuki
    Department of Clinical Laboratory, Kurashiki central Hospital
  • KENRI Tsuyoshi
    Department of Bacteriology II, National Institute of Infectious Diseases
  • NAKAJIMA Hiroshi
    Department of Bacteriology, Okayama Prefectural Institute for Environmental Science and Public Health
  • SHIBAYAMA Keigo
    Department of Bacteriology II, National Institute of Infectious Diseases

Bibliographic Information

Other Title
  • 市中病院における<i>Mycoplasma pneumoniae </i>の抗菌薬感受性および 臨床経過に関する検討
  • 市中病院におけるMycoplasma pneumoniaeの抗菌薬感受性および臨床経過に関する検討
  • シ ジュウ ビョウイン ニ オケル Mycoplasma pneumoniae ノ コウキンヤク カンジュセイ オヨビ リンショウ ケイカ ニ カンスル ケントウ

Search this article

Abstract

Recently, reports of macrolide-resistant strains of Mycoplasma pneumoniae have been increasing. We examined the antimicrobial susceptibility and clinical significance in patients with M. pneumoniae. Seventy patients in whom M. pneumoniae was detected from 2008 to 2012 were included in the study, and compared with patients between 2003 and 2006. There were no macrolide-resistant strains detected in the 38 strains from 2003 to 2006, but from 2008 to 2012, out of the 70 strains 46 (65.7％) were positive for the macrolide resistant 23SrRNA gene mutant (A2063G), which is consistent with recent trends. Comparison between cases of macrolide resistant strains and those with macrolide sensitive strains did not reveal a significant difference in the hospitalization period. The approximate duration of fever was 7 days ; for both cases : those who received effective antimicrobials as the initial therapy, and for those with macrolide sensitive strains. It seems that the duration of fever depends on susceptibility to the initial antimicrobials regardless of macrolide resistance. There were some patients that improved without use of quinolone or minocycline, though macrolide resistant strains were detected. These patients did not reveal extension of the hospital stay nor aggravation of pneumonia. This suggests that a macrolide drug might be the first choice drug for M. pneumoniae even now, and a change of drug should be considered when fever duration is long.

Journal

  • Kansenshogaku Zasshi

    Kansenshogaku Zasshi 89 (4), 458-464, 2015

    The Japanese Association for Infectious Diseases

References(14)*help

See more

Keywords

Details 詳細情報について

Report a problem

Back to top